Co-Authors
This is a "connection" page, showing publications co-authored by Savas Tay and Glenn C. Randall.
Connection Strength
0.411
-
A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets. Nat Biotechnol. 2023 01; 41(1):128-139.
Score: 0.054
-
SARS-CoV-2 Diverges from Other Betacoronaviruses in Only Partially Activating the IRE1a/XBP1 Endoplasmic Reticulum Stress Pathway in Human Lung-Derived Cells. mBio. 2022 10 26; 13(5):e0241522.
Score: 0.054
-
SARS-CoV-2 diverges from other betacoronaviruses in only partially activating the IRE1a/XBP1 ER stress pathway in human lung-derived cells. bioRxiv. 2022 Jun 13.
Score: 0.053
-
A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19. Res Sq. 2022 Jun 07.
Score: 0.053
-
Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv. 2022 Feb 25; 8(8):eabi6110.
Score: 0.052
-
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021 08 20; 373(6557):931-936.
Score: 0.050
-
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response. bioRxiv. 2021 Mar 10.
Score: 0.048
-
Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro. bioRxiv. 2020 Sep 01.
Score: 0.047